- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03191812
The Short-term Effects of Noninvasive Electrical Brain Stimulation on Dual Tasking in Older Adults
14 maart 2022 bijgewerkt door: Brad Manor, Hebrew SeniorLife
Optimization of Transcranial Direct Current Stimulation (tDCS) for Dual Task Performance in Older Adults With and Without a History of Falls
The tDCS & Dual Tasking study will compare the effects of transcranial Direct Current Stimulation (tDCS) targeting three different cortical regions (as well as sham stimulation) on dual task standing and walking in older adults with and without a recent history of recurrent falls.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The ability to stand and walk safely, especially while performing additional cognitive tasks like talking, reading or decision making, is critical to the preservation of functional independence into old age.
Such "dual tasking" often impairs balance, even in healthy older adults and those with greater dual task "costs" are more likely to suffer future falls.
Transcranial direct current stimulation (tDCS) is a safe, noninvasive and inexpensive means of modulating activity across cortical networks.
A single, 20-minute session of tDCS facilitates brain activity for up to 24 hours.
Through Dr. Manor's previous research in healthy older adults, he has discovered that just 20 minutes of tDCS targeting the left dorsolateral prefrontal cortex (dlPFC)-a region involved in both cognitive and motor function-immediately reduces the dual task costs to balance when standing and walking, and improves performance in the timed up-and-go (TUG) test of mobility.
However, there are several brain networks with known involvement in balance control and dual tasking, and the optimal brain region to target to improve dual task capacity has not been established.
The proposed study will be a double-blinded, sham-controlled study in which older adults both with and without a history of falling undergo dual task assessments immediately before and after single, 20-minute sessions of tDCS designed to target several different brain regions with known involvement in dual tasking and the maintenance of balance.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
61
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Tel Aviv, Israël, 64239
- Laboratory for Gait and Neurodynamics, Tel Aviv Sourasky Medical Center
-
-
-
-
Massachusetts
-
Roslindale, Massachusetts, Verenigde Staten, 02131
- Hebrew Rehabilitation Center
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
65 jaar en ouder (Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
"Faller" group
- Aged 65 years and older
- Able to read, write and communicate in English
- Self-report of 2 or more falls within the past 6 months
"Non-Faller" Group
- Aged 65 years and older
- Able to read, write, and communicate in English
- Self-report of 1 or no (zero) falls within the past 6 months
Exclusion Criteria:
- Self-reported diagnosis of Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, history of stroke or other neurodegenerative disorder.
- Self-reported active cancer for which chemo-/radiation therapy is being received.
- Hospitalization within the past 3 months due to acute illness or as a result of a musculoskeletal injury significantly affecting gait and balance.
- Montreal Cognitive Assessment score <18, or insufficient understanding of study procedures following review of the Informed Consent Form. Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.
- Inability to stand or ambulate unassisted for at least 25 feet.
- Contraindications to tDCS, including a reported seizure within the past two years, use of neuro-active drugs, the risk of metal objects in the brain, skull, or head, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant), or the presence of any active dermatological condition, such as eczema, on the scalp (see appendix for standardized tDCS screening questionnaire).
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Sham-vergelijker: Sham Stimulation
The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation.
The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
|
There will be three different tDCS targets as well as a sham stimulation condition.
The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
|
|
Experimenteel: M1 Stimulation
The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
|
There will be three different tDCS targets as well as a sham stimulation condition.
The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
|
|
Experimenteel: DLPFC Stimulation
The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
|
There will be three different tDCS targets as well as a sham stimulation condition.
The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
|
|
Experimenteel: M1+DLPFC Stimulation
The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
|
There will be three different tDCS targets as well as a sham stimulation condition.
The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dual task cost to standing postural sway speed
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
The dual task cost to standing postural sway speed will be calculated from trials of standing with and without simultaneous performance of a serial subtraction cognitive task.
The dual task cost will be calculated as the percent change in sway speed from single- to dual-task conditions.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Dual task cost to gait speed when walking
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
The dual task cost to gait speed when walking will be calculated from trials of walking with and without simultaneous performance of a serial subtraction cognitive task.
The dual task cost will be calculated as the percent change in gait speed from single- to dual-task conditions.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dual task cost to postural sway area
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
The dual task cost to standing postural sway area will be calculated from trials of standing with and without simultaneous performance of a serial subtraction cognitive task.
The dual task cost will be calculated as the percent change in postural sway area from single- to dual-task conditions.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Dual task cost to gait variability when walking
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
The dual task cost to gait variability when walking will be calculated from trials of walking with and without simultaneous performance of a serial subtraction cognitive task.
Gait variability will be defined as the coefficient of variation about the average stride time (stride times defined by the time between consecutive heel strides of the same leg).
The dual task cost will be calculated as the percent change in gait variability from single- to dual-task conditions.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Single task postural sway speed
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Single task postural sway speed will be calculated from trials of standing without simultaneous performance of a serial subtraction cognitive task.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Single task postural sway area
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Single task postural sway area will be calculated from trials of standing without simultaneous performance of a serial subtraction cognitive task.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Single task gait speed variability when walking
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Single task gait variability when walking will be calculated from trials of walking without simultaneous performance of a serial subtraction cognitive task.
Gait variability will be defined as the coefficient of variation about the average stride time (stride times defined by the time between consecutive heel strides of the same leg).
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Single task gait speed when walking
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Single task gait speed when walking will be calculated from trials of walking without simultaneous performance of a serial subtraction cognitive task.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Mobility
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Mobility will be assessed using the Timed Up-and-Go test in which the amount of time it takes for the participant to stand up from a chair, walk three meters, turn around a cone, walk back, and sit down is recorded.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Executive function
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Executive function will be assessed using the Stroop test.
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Cognitive processing speed
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT).
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS.
|
|
Attention
Tijdsspanne: This outcome will be assessed immediately before and after each 20-minute session of tDCS
|
Attention will be assessed using the Visual Search and Attention Test (VSAT).
|
This outcome will be assessed immediately before and after each 20-minute session of tDCS
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Brad Manor, Institute for Aging Research, Hebrew SeniorLife
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
26 mei 2017
Primaire voltooiing (Werkelijk)
26 november 2019
Studie voltooiing (Werkelijk)
26 mei 2021
Studieregistratiedata
Eerst ingediend
15 juni 2017
Eerst ingediend dat voldeed aan de QC-criteria
15 juni 2017
Eerst geplaatst (Werkelijk)
19 juni 2017
Updates van studierecords
Laatste update geplaatst (Werkelijk)
15 maart 2022
Laatste update ingediend die voldeed aan QC-criteria
14 maart 2022
Laatst geverifieerd
1 maart 2022
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 2016-26
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op transcranial Direct Current Stimulation (tDCS)
-
King's College LondonVoltooidVreetbui syndroomVerenigd Koninkrijk
-
Minneapolis Veterans Affairs Medical CenterCenter for Veterans Research and EducationVoltooidObesitas | Impulsiviteit | Dwangmatig te veel etenVerenigde Staten
-
Onze Lieve Vrouw HospitalOnbekendAandachtstekortstoornis met hyperactiviteit (ADHD) | Aandachtstekortstoornis (ADD)België
-
University of RochesterBrain & Behavior Research FoundationVoltooid
-
Hospital Universitari Vall d'Hebron Research InstituteVoltooidAutisme Spectrum Stoornis | Aandachtstekortstoornis met hyperactiviteitSpanje
-
School of Health Sciences GenevaUniversity Hospital, GenevaWervingHartinfarct | Gangwerk, hemiplegieZwitserland
-
Beth Israel Deaconess Medical CenterNational Institute on Deafness and Other Communication Disorders (NIDCD)WervingCognitieve verandering | Traumatische hersenschade | Verworven hersenletsel | Cognitief symptoom | Moeilijkheden om woorden te vindenVerenigde Staten
-
Hospital de Clinicas de Porto AlegreWervingtDCS | EEG | Duloxetine | Fibromyalgie (FM) | BDNFBrazilië
-
Beth Israel Deaconess Medical CenterVoltooid
-
University of BernWerving